Oxetanones

A pancreas lipase-inhibiting composition comprising an effective amount of a racemic compound of the formula ##STR26## wherein R.sup.1 and R.sup.2 are independently C.sub.1-17 -alkyl which is saturated or optionally interrupted by up to 8 double or triple bonds and/or optionally interrupted by an O or S atom, which is present in other than the .alpha.-position to an unsaturated C. atom;

• or phenyl, benzyl or --C.sub.6 H.sub.4 --X--C.sub.6 H.sub.5 ring-substituted by 0 to 3 C.sub.1-6 -alkyl-(O or S).sub.1 or 0 groups, and X is oxygen, sulfur or (CH.sub.2).sub.0-3, with the proviso that when R.sup.1 is n-hexyl and R.sup.2 is undecyl or 2Z,5Z-undecadienyl, at least one of the asymmetric C-atoms present in the oxetanone ring and in the .beta.-position to the latter has the R-configuration, an enantiomer or diastereomer thereof, or a pharmaceutically acceptable acid addition salt thereof, and a pharmaceutically inert carrier material.

A composition according to claim 19, wherein R.sup.1 is methyl, propyl, hexyl, decyl, hexadecyl, allyl, benzyl or ethyl;

• and R.sup.2 is methyl, undecyl, 3-butenyl, 3-undecenyl, 8,11-heptadecadienyl, phenoxyphenyl or heptadecyl.